The short version of freeze-thaw cycle fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-24 and is reviewed periodically as new material appears.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
The first 7-Eleven store to open in Canada was in Calgary, Alberta, on June 29, 1969. There are 562 7-Eleven stores in Canada as of December 2022. Winnipeg, Manitoba, has the world's largest number of Slurpee consumers, with an estimated 1,500,000 Slurpees sold since the first 7-Eleven opened on March 21, 1970. All 7-Eleven locations in Canada are corporate operated. Like its U.S. counterparts every July 11 the stores offer free Slurpees on "7-Eleven Day". Many 7-Eleven locations offer petrol stations, either supplied by national distributors such as Imperial Oil and Petro-Canada, or under private label 7-Eleven branding. In March 2016, 7-Eleven acquired 148 Esso stations in Alberta and British Columbia from Imperial Oil for C$2.8 billion, with many of their convenience stores being converted to 7-Eleven. Some locations were not converted, and operate under the banner "smartstop 24/7" with their existing store formats, typically inherited from On the Run. In April 2025, 7-Eleven announced that it would convert its remaining 7-Eleven-branded petrol stations in Alberta and Ontario to either Esso, Mobil, or Petro-Canada. In November 2005, 7-Eleven started offering the Speak Out Wireless cellphone service in Canada. 7-Eleven locations also featured CIBC ATMs—in June 2012, these machines were replaced with ATMs operated by Scotiabank. 7-Eleven abandoned the Ottawa, Ontario, market in December 2009 after selling its six outlets to Quickie Convenience Stores, a regional chain.
Direct measurements of the Venusian atmosphere by spatial probes point to very harsh conditions, likely making Venus an uninhabitable world, even for the most extreme forms of life known on Earth. The extremely low water activity of the desiccated Venusian atmosphere represents the very limiting factor for life, much more severe than the infernal conditions of temperature and pressure, or the presence of sulfuric acid. Astrobiologists presently consider that more favorable conditions could be encountered in the clouds of Jupiter where a sufficient water activity could prevail in the atmosphere provided that other conditions necessary for life are also met in the same environment (sufficient supply of nutrients and energy in a non-toxic medium).
is the distance traveled by the liquid. More extensive models account for paper tortuosity, pore radius, and paper deformation. Once the medium is fully wetted, subsequent flow is laminar and follows Darcy's law. The average velocity of fluid flow is generalized as,
== Evolution == The GHR gene is used in animals as a nuclear DNA phylogenetic marker. The exon 10 has first been experienced to explore the phylogeny of the major groups of Rodentia. GHR has also proven useful at lower taxonomic levels, e.g., in octodontoid, arvicoline, muroid, murine, and peromyscine rodents, in arctoid and felid carnivores, and in dermopterans. Note that the GHR intron 9 has also been used to investigate the mustelid and hyaenid carnivores phylogenetics.
Sources: en.wikipedia.org
In 1840, the Cossack hosts included the Don, Black Sea, Astrakhan, Little Russia, Azov, Danube, Ural, Stavropol, Mesherya, Orenburg, Siberian, Tobolsk, Tomsk, Yeniseisk, Irkutsk, Sabaikal, Yakutsk, and Tartar voiskos. In the 1890s, the Ussuri, Semirechensk, and Amur Cossacks were added; the last had a regiment of elite mounted rifles. Increasingly as the 19th century went on, the Cossacks served as a mounted para-military police force in all of the various provinces of the vast Russian Empire, covering a territory stretching across Eurasia from what is now modern Poland to the banks of the river Amur that formed the Russian-Chinese border. The police forces of the Russian Empire, especially in rural areas, were undermanned owing to the low wages while the officers of the Imperial Russian Army disliked having their units deployed to put down domestic unrest, which was viewed as destructive of morale and possibly an incentive to mutiny. For the government, deploying Cossacks as a para-military police force was the best solution as the Cossacks were viewed as one of the social groups most loyal to the House of Romanov while their isolation from local populations was felt to make them immune to revolutionary appeals. Traditionally, Cossacks were viewed in Russia as dashing, romantic horsemen with a rebellious and wild aura about them, but their deployment in the role of a mounted police force gave them a "novel" image as a rather violent and thuggish institution fiercely committed to upholding the social order.
Mercedes-Benz used the alloy Elektron in the bodywork of an early model Mercedes-Benz 300 SLR; these cars competed in the 1955 World Sportscar Championship including a win at the Mille Miglia, and at Le Mans where one was involved in the 1955 Le Mans disaster when spectators were showered with burning fragments of Elektron. Porsche used magnesium alloy frames in the 917/053 that won Le Mans in 1971, and continues to use magnesium alloys for its engine blocks due to the weight advantage. Volkswagen Group has used magnesium in its engine components for many years. Mitsubishi Motors uses magnesium for its paddle shifters. BMW used magnesium alloy blocks in their N52 engine, including an aluminium alloy insert for the cylinder walls and cooling jackets surrounded by a high-temperature magnesium alloy AJ62A. The engine was used worldwide between 2005 and 2011 in various 1, 3, 5, 6, and 7 series models; as well as the Z4, X1, X3, and X5. Chevrolet used the magnesium alloy AE44 in the 2006 Corvette Z06. Both AJ62A and AE44 are recent developments in high-temperature low-creep magnesium alloys. The general strategy for such alloys is to form intermetallic precipitates at the grain boundaries, for example by adding mischmetal or calcium.
== Adverse effects == Common side effects (in about 1–10% of patients) include gastrointestinal problems typical of NSAIDs, such as nausea, diarrhoea, stomach pain, and peptic ulcer; central nervous effects like headache and dizziness; and skin reactions. Gastrointestinal tolerability is better than that of the related drug indometacin. Severe allergic reactions and haematopoietic disorders occur in fewer than 0.01% of patients.
is the rate constant for propagation of a polymer chain ending in monomer 1 (or A) by addition of monomer 2 (or B). The composition and structural type of the copolymer depend on these reactivity ratios r1 and r2 according to the Mayo–Lewis equation, also called the copolymerization equation or copolymer equation, for the relative instantaneous rates of incorporation of the two monomers.
== Society and culture == Golodirsen is one of the very few FDA-approved exon-skipping therapy for Duchenne muscular dystrophy, although the clinical benefits of the medication are yet to established. While the development of golodirsen needed huge financing, it is only applicable to a small subset of people with Duchenne muscular dystrophy. Sarepta Therapeutics has announced that golodirsen will cost in parity with eteplirsen, another medication of a similar kind, which may be as high as US$300,000 per year. Also, the accelerated approval of golodirsen has paved the way for people to have early access to the medication, at the same time, it is shrouded with controversy over a number of issues. A double-blind placebo-controlled confirmatory trial (NCT02500381) is ongoing to resolve the issues.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.